큐리언트는 6일 CDK7 억제 기전의 항암치료제 Q901의 미국 임상을 위해 식품의약국(FDA)에 임상 1/2상 시험을 신청했다고 공시했다. Q901은 세포 주기 조절 인자(Cell cycle regulator) 중 핵심이 되는 CDK7을 저해하는 항암제다. 경쟁약물 대비 월등한 선택성으로 기전적, 효능적 차별성을 ....

Article Source : 바이오스펙테어터
Link : http://www.biospectator.com/view/news_view.php?varAtcId=14983

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20211122006506/en/Qurient-Announces-Collaboration-Agreement-with-MSD-to-Evaluate-Selective-Triple-Inhibitor-Q702-in-Combination-With-KEYTRUDA%C2%AE-pembrolizumab

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202111237480i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202110146850i

Article Source : 한국경제
Link : https://www.hankyung.com/finance/article/202107297778i

Article Source : 한국경제
Link : https://www.hankyung.com/finance/article/202104122123i

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2021032215043796600

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202101263518i

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20210126005764/en/Qurient-Enrolls-First-Patient-in-Q702-U.S.-Phase-1-Study

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2021011411094667202

Article Source : Korea Biomedical Review
Link : http://www.koreabiomed.com/news/articleView.html?idxno=10169

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202101117023i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202012043320i